Effects of exercise prescription on daily physical activity and maximal exercise capacity in coronary artery disease patients with and without type 2 diabetes

Jaana J. Karjalainen1,2, Antti M. Kiviniemi1, Arto J. Hautala1, Jarkko Niva2, Samuli Lepojärvi2, Timo H. Mäkikallio2, Olli-Pekka Piira2, Heikki V. Huikuri2,† and Mikko P. Tulppo1,2,†

1Department of Exercise and Medical Physiology, Verve Research, and 2Department of Internal Medicine, Institute of Clinical Medicine, University of Oulu, Oulu, Finland

Correspondence
Mikko Tulppo, Department of Exercise and Medical Physiology, Verve Research, PO Box 404, Kauhakortteli 13, FI-90101, Oulu, Finland
E-mail: mikko.tulppo@verve.fi
†equal senior authorship.

Accepted for publication
Received 06 September 2011; accepted 31 May 2012

Key words
accelerometer; cardiac patients; exercise intensity; fitness; physical training

Summary

Background: Promotion of and adherence to increased physical activity (PA) is an important part of the prevention and treatment of coronary artery disease (CAD). We hypothesized that individually tailored home-based exercise prescriptions will increase long-term PA and maximal exercise capacity among CAD patients without and with type 2 diabetes (CAD+T2D).

Methods: Physical activity of patients with CAD (n = 44) and CAD+T2D (n = 39), matched by age, sex and ejection fraction, was measured over 5 days with an accelerometer pre- and postexercise prescription. PA was assessed as the average time per day of moderate (METs < 3.5) and high (METs > 5) intensities. Six-month exercise prescriptions were introduced based on individual maximal heart rate reserve.

Results: At the baseline, patients with CAD+T2D engaged in less moderate-intensity PA (2:40 ± 1:23 versus 3:24 ± 1:17 h, P = 0.014) and exhibited a non-significant trend to reduced high-intensity PA (2:08 ± 2:57 versus 5:02 ± 9:19 min, P = 0.091) compared with patients with CAD. High-intensity PA increased markedly in CAD (5:02 ± 9:19 versus 9:59 ± 15:03 min) and patients with CAD+T2D (2:08 ± 2:57 versus 6:14 ± 10:18 min) after exercise prescription (main effect for time P = 0.001). Also maximal exercise capacity increased in both groups (main effect for time P<0.001).

Conclusion: Patients with CAD with T2D are physically less active than CAD patients without diabetes in their daily life. Individually tailored home-based exercise prescriptions are an effective way to promote more active lifestyles and improve fitness in both patient groups.

Introduction

Type 2 diabetes (T2D) is a common worldwide disease and a marked independent risk factor for coronary artery disease (CAD) and cardiovascular mortality (Haffner et al., 1998; Decode Study Group, 2001; Vaccaro et al., 2004; Junntila et al., 2010). Diabetic patients with a previous myocardial infarction have a higher risk of premature mortality (Haffner et al., 1998; Decode Study Group, 2001) and sudden cardiac death (Decode Study Group, 2001; Junntila et al., 2010) compared with non-diabetic patients with a myocardial infarction.

Regular physical activity (PA) is highly recommended for both CAD (Miller et al., 1997; Jolliffe et al., 2001; Taylor et al., 2004) and CAD+T2D patients (Thomas et al., 2006; Colberg et al., 2010). It is well established that long-term PA and exercise improve various health indices, such as cholesterol levels, blood pressure and cardiorespiratory fitness, in both patient groups (Hambrecht et al., 1993; Miller et al., 1997; Taylor et al., 2004) and reduce the risk of cardiovascular and all-cause mortality (Jolliffe et al., 2001; Taylor et al., 2004; Moholdt et al., 2008). Regular PA also has a positive influence on blood glucose control and insulin sensitivity in patients with diabetes (Boule et al., 2001; Snowling & Hopkins, 2006; Thomas et al., 2006; Colberg et al., 2010).

Despite the well-known health benefits of regular PA and exercise, the majority of patients with CAD or T2D does not regularly engage in PA and do not meet the PA guidelines (Hays & Clark, 1999; Nelson et al., 2002; Thomas et al., 2004;...
Methods

Subjects and study protocol

This study is part of the ARTEMIS (Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection) study which has been registered at ClinicalTrials.gov, Record 1539/31/06. The patients in the ARTEMIS study have been recruited from a consecutive series of CAD patients with and without T2D (1:1 matched in terms of age, sex, prior myocardial infarction and revascularization procedure, Table 1) who underwent coronary angiography in the Division of Cardiology of the Oulu University Hospital. The ARTEMIS exercise prescription sub-study is a 2-year randomized and controlled exercise prescription trial for patients with CAD + T2D and CAD. In this study, we report PA data and the effects of exercise prescription during the first six months. CAD and its severity were assessed by measurement of the Syntax score from the coronary angiography (Sianos et al., 2005). T2D was defined according to the WHO, 1999 (WHO, 1999) criteria. Patients who had a fasting plasma glucose level ≥ 7.0 mmol l⁻¹ or were on hypoglycaemic medication based on prior diagnosis of diabetes were classified as having T2D. Patients without T2D were normoglycemic, defined as a plasma glucose level < 6.1 mmol l⁻¹ in the fasting state and a plasma glucose level < 8.8 mmol l⁻¹ during a two-hour glucose tolerance test.

Patient selection for this study is presented in Fig. 1. There were 346 patients with CAD and 461 patients with CAD+T2D in the ARTEMIS database. Of those patients, 497 (198 patients with CAD and 299 patients with CAD+T2D) were excluded from the exercise prescription study owing to the following criteria: advanced age (>75 years), body mass index (BMI) >40 kg m⁻², NYHA class III or IV, left ventricular ejection fraction (LVEF) <40%, scheduled cardiac revascularization surgery, heart failure, unstable angina pectoris, severe peripheral atherosclerosis, diabetic retinopathy or neuropathy or other inability to perform regular home-based exercise, for example, because of musculoskeletal problems. Altogether 224 out of 310 suitable patients (72%) were willing to participate and 113 of those patients (51 patients with CAD and 62 patients with CAD+T2D) were randomly selected into the exercise prescription group and 111 into a control group. Patients who did not want to (n = 16) or did not properly carry out the PA measurement (n = 7) and patients who did not participate in the 6-month follow-up measurements (n = 7) were excluded. In total, 44 patients with CAD, and 39 patients with CAD+T2D were included in the analyses of this study.

The following laboratory measurements were performed in the Department of Exercise and Medical Physiology at Verve (Oulu, Finland): body composition, glycated haemoglobin (HbA1c) level (Afinion™ AS100, Axis-Shield PoC AS, Oslo, Norway) and blood pressure (average of two measures) in a supine position after a 10-min resting period (Tango, SunTech, Raleigh, NC, USA). The subjects performed a maximal exercise test on a bicycle for assessment of peak oxygen uptake (VO₂peak). The subjects were not allowed to eat or drink coffee for 3 h before the tests. Strenuous PA and use of alcohol were prohibited during the test day and on the preceding day. All the measurements were repeated after the 6-month exercise prescription. The study was performed according to the Declaration of Helsinki, and the local committee of research ethics of the Northern Ostrobothnia Hospital District approved the protocol, and all the subjects gave written informed consent.

Assessment of peak oxygen uptake

The patients performed an incremental symptom-limited maximal exercise test on a bicycle ergometer (Monark Ergomedic 839 E, Monark Exercise AB, Vansbro, Sweden) with 15-lead ECG recordings (GE Healthcare, CAM-14, Freiburg, Germany). The test was started at 30 W, and the work rate was increased by 15 W in men and 10 W in women every minute until voluntary exhaustion or ST depression > 0.2 mV in ECG.
Ventilation and gas exchange (M909 Ergospirometer, Mikiro, Kuopio, Finland) were monitored continuously during the test. The highest 1-min mean value of oxygen consumption was expressed as VO$_{2\text{peak}}$. Maximal workload (W) and maximal metabolic equivalents (METs) were calculated as the average workload and METs during the last minute of the test.

### Assessment of physical activity

PA was measured over five consecutive days during waking hours with a wristwatch equipped with a one-dimensional accelerometer (Polar AW200 Activity Watch; Polar Electro Oy, Kempele, Finland). Accelerometer technology has been recently validated and compared with energy expenditure measured by indirect calorimetry (Brugniaux et al., 2010). According to previous studies (Gretebeck & Montoye, 1992; Trost et al., 2005), 5 days of PA monitoring including weekend days is enough to make possible the reliable estimation of daily PA among adults. In present study PA measurement was started within 2 days after the laboratory measurements so that weekend days were included in the measurement days. Patients were advised to wear the accelerometer during all waking hours and carry on their normal daily routine.

Physical activity time (METs$^2$/C$_2$1$^2$) per day was calculated at five different intensity levels and analysed separately for moderate (METs = 2–3, ‘slow walking or walking’) and high (METs > 5 ‘brisk walking or higher’) intensity. Daily PA during waking hours was also expressed in average METs. Average METs were calculated as the patients mean daily energy expenditure (kcal) divided by his or her body weight divided by mean waking hours per day. One MET corresponds to an energy expenditure of approximately 1 kcal per kilogram.
of body weight per hour, or an oxygen uptake of 3.5 ml·kg⁻¹·min⁻¹. Reassessment of PA was made during 5 consecutive days including weekend days after the completion of the 6-month exercise period.

**Exercise prescription**

The controlled 6-month exercise prescription was based on current guidelines (Piepoli et al., 2010) and consisted of home-based endurance training (30 min) and strength training (30 min). During the first 3 months the exercise prescription was four heart-rate-controlled exercise sessions per week; three endurance training and one strength training session. The intensity of the endurance training was stated as between 50% and 60% of the heart rate reserve, using a heart rate recorder (Polar F1, Polar Electro Oy, Kempele, Finland). After 3 months, the exercise prescription was five exercise sessions per week, two endurance training sessions at 50–60% of the heart rate reserve, two endurance training sessions at 60–70% of the heart rate reserve and one home-based strength training session.

Exercise prescription was introduced after baseline laboratory and PA measurements by specialist of sports medicine or physiotherapist specialized in cardiac rehabilitation in the Department of Exercise and Medical Physiology at Verve (Oulu, Finland). After 3 months, the exercise prescription was five exercise sessions per week, two endurance training sessions at 50–60% of the heart rate reserve, two endurance training sessions at 60–70% of the heart rate reserve and one home-based strength training session.

Exercise prescription was introduced after baseline laboratory and PA measurements by specialist of sports medicine or physiotherapist specialized in cardiac rehabilitation in the Department of Exercise and Medical Physiology at Verve (Oulu, Finland). The patients got a daily diary which was marked training days and resting days. The target duration of exercise sessions and the actual training heart rate zones were included in the diary. The patients also got oral and written instructions how to use the HR recorder and how to write down the duration and the average heart rate of every training session in the diary. During 6-month exercise period the patients were contacted by specialist of sports medicine or physiotherapist in time point 1 and 3 months to check if there is problem with the adherence of exercise prescription or the use of HR recorder.

Weekly training load was calculated as the mean training impulse (TRIMP) using the following formula: TRIMP = ABC, in which A is exercise time (min), B is heart rate (proportionally to the heart rate reserve), and C is $e^{0.92B}$ for men and $e^{0.67B}$ for women (Morton et al., 1990). Target TRIMP per week for endurance training and strength training was calculated using the same formula. Calculating target TRIMP for endurance training B was stated as an average of target heart rate (55% or 65% of the heart rate reserve) and in strength training B was defined as 90% of the target heart rate of light endurance training based on our previous experience (Hautala et al., 2006). All the patients were included in the analysis regardless if their realized TRIMP were under or over the target TRIMP.

**Statistical analyses**

A Kolmogorov–Smirnov Z-test was used to examine the Gaussian distribution of the data. At the baseline, the groups were compared using a t-test for independent samples, a Mann–Whitney U-test, or a chi-square test, accordingly. Additionally, between-group comparisons in PA variables at pre-prescription conditions were adjusted for BMI and exercise capacity (METs_max), and exercise test variables were adjusted for BMI using ANCOVA. For variables having only baseline values and training realization (TRIMPs), a t-test for independent samples, a Mann–Whitney U-test, or a chi-square test was applied accordingly. The effects of the exercise prescription were analysed by two-factor ANOVA with time and interventions. When significant time x intervention interaction was observed, a post hoc analysis was performed using a paired t-test between pre- and postprescription values within each group and a t-test for independent samples for between-group comparisons at pre- and postprescription conditions. PA at high intensity was the only follow-up variable that had non-Gaussian distribution and was transformed into natural logarithm.
before parametric statistical tests. Statistical analyses of the data were performed with SPSS software (SPSS 19.0, SPSS Inc., Chicago, IL, USA). Statistical significance was defined as a P-value <0·05 for all tests.

Results

Descriptive results

The characteristics of the study groups, including comparisons between groups, are presented in Table 1. The patients with CAD+T2D had a higher BMI than the patients with CAD (P < 0·001) and they had a higher HbA1c level (P<0·001 compared with the patients with CAD). Blood pressure, angiographic severity of CAD, ejection fraction or smoking habits did not differ between the groups (Table 1). The mean duration of diabetes was 72 ± 97 months. The history of acute myocardial infarction (AMI) did not differ between CAD+T2D and patients with CAD (Table 1). The mean duration between AMI and the begin of the study was 48 ± 57 months in CAD+T2D patients and 19 ± 21 months in patients with CAD (P = 0·249).

Beta blockers, calcium antagonists, nitrates and diuretics were more commonly used by the CAD+T2D than the patients with CAD (Table 1). During exercise prescription, 13 (30%) patients with CAD and 13 (33%) patients with CAD+T2D changed their medication (P = 0·710 between groups). Typically, the changes of medication concerned with the beta blocker (started 2 patients and reduced 8 patients), antiplatelet therapy (stopped in 6 patients) and angiotensin conversion enzymes inhibitor or angiotensin receptor blocker (increased 3 and reduced 3 patients).

Physical activity before exercise prescription

The mean waking time was 15:00 ± 1:20 h per day in patients with CAD+T2D and 15:15 ± 1:05 h per day in patients with CAD (P = 0·338). Before exercise prescription, total PA time per day was lower in the patients with CAD+T2D than in the patients with CAD (2:42 ± 1:23 versus 3:29 ± 1:18 h, P = 0·010) (Fig. 2a). Divided separately into moderate and high-intensity levels, the patients with CAD+T2D engaged in less moderate-intensity PA than the patients with CAD (P = 0·014) (Table 2) and they exhibited a non-significant trend to reduced high-intensity PA (2:08 ± 2:57 versus 5:02 ± 9:19 min, P = 0·091) (Fig. 2b). Average METs during waking hours were lower in the patients with CAD+T2D than in the patients with CAD (P = 0·003) (Table 2). However, differences in PA variables between groups did not remain statistically significant after adjustment for BMI and exercise capacity (Table 2, Fig. 2a,b).

Physical activity after exercise prescription

The effects of exercise prescription on PA are shown in Table 2 and Fig. 2a,b. There were no significant changes in total or moderate-intensity PA in either group (Table 2, Fig. 2a). However, high-intensity PA increased in the patients with CAD (from 5:02 ± 9:19 to 9:59 ± 15:03 min) and in the patients with CAD+T2D (from 2:08 ± 2:57 to 6:14 ± 10:18 min, main effect for time P = 0·001) (Fig. 2b). There was no main effect for time x group interaction in any PA variables in patients with CAD or CAD+T2D (Table 2, Fig. 2a,b).

Adherence to exercise prescription

Adherence to the tailored exercise prescription, including comparisons between patient groups, is presented in Table 3. Targeted and realized TRIMPs did not differ between the patients with CAD and CAD+T2D at any condition. The weekly TRIMP of endurance training was significantly higher than the prescription during the first 3 months, but did not differ from the planned training TRIPMs during the last 3 months.

Maximal exercise test

The results of the maximal exercise test, including comparisons between groups, are given in Table 2. At the baseline the
Table 2  Physical activity and maximal exercise test of the study groups before and after exercise prescription.

<table>
<thead>
<tr>
<th></th>
<th>Pre CAD (n = 44)</th>
<th>CAD+ T2D (n = 39)</th>
<th>Adj. for BMI</th>
<th>Adj. for METsmax</th>
<th>Adj. for BMI+METsmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PA at moderate intensity, hour</td>
<td>3.24 ± 1.77</td>
<td>2.40 ± 1.33</td>
<td>0.118</td>
<td>0.165</td>
<td>0.193</td>
</tr>
<tr>
<td>METsmax, per day</td>
<td>1.9 ± 0.4</td>
<td>1.7 ± 0.3</td>
<td>0.132</td>
<td>0.159</td>
<td>0.249</td>
</tr>
<tr>
<td>Maximal exercise test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>max workload, W</td>
<td>159 ± 47</td>
<td>142 ± 36</td>
<td>0.348</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>HRmax, bpm</td>
<td>139 ± 19</td>
<td>128 ± 19</td>
<td>0.125</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>METsmax</td>
<td>8.1 ± 2.0</td>
<td>6.5 ± 1.6</td>
<td>0.198</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>VO2peak, l·min⁻¹</td>
<td>2.11 ± 0.6</td>
<td>1.92 ± 0.5</td>
<td>0.181</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>VO2peak, ml·kg⁻¹·min⁻¹</td>
<td>27.2 ± 7.2</td>
<td>21.6 ± 5.7</td>
<td>0.085</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Table 3  Adherence to the exercise prescription in patients groups.

<table>
<thead>
<tr>
<th></th>
<th>Pre CAD (n = 44)</th>
<th>CAD+ T2D (n = 39)</th>
<th>P value between groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training 1–3 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endurance training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>141 ± 38</td>
<td>146 ± 35</td>
<td>0.286</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>212 ± 112</td>
<td>232 ± 131</td>
<td>0.465</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Strength training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>22 ± 10</td>
<td>20 ± 10</td>
<td>0.082</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>21 ± 31</td>
<td>24 ± 46</td>
<td>0.902</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P = 0.026</td>
<td>P = 0.011</td>
<td></td>
</tr>
<tr>
<td>Training 4–6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endurance training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>225 ± 50</td>
<td>225 ± 54</td>
<td>0.956</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>268 ± 160</td>
<td>278 ± 157</td>
<td>0.989</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P = 0.093</td>
<td>P = 0.204</td>
<td></td>
</tr>
<tr>
<td>Strength training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>22 ± 10</td>
<td>20 ± 10</td>
<td>0.082</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>17 ± 19</td>
<td>25 ± 55</td>
<td>0.240</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P = 0.002</td>
<td>P = 0.001</td>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SD; n, number of subjects; CAD, coronary artery disease; T2D, type 2 diabetes; BMI, body mass index; PA, physical activity; METsmax, average value of metabolic equivalent measured during waking hours; HR, heart rate; VO2peak, peak oxygen uptake; °<p<0.05 and †p<0.01 between the groups without adjustments; ‡p<0.05 between pre and postmeasurements.

Table 3  Adherence to the exercise prescription in patients groups.

<table>
<thead>
<tr>
<th></th>
<th>Pre CAD (n = 44)</th>
<th>CAD+ T2D (n = 39)</th>
<th>P value between groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training 1–3 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endurance training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>141 ± 38</td>
<td>146 ± 35</td>
<td>0.286</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>212 ± 112</td>
<td>232 ± 131</td>
<td>0.465</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Strength training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>22 ± 10</td>
<td>20 ± 10</td>
<td>0.082</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>21 ± 31</td>
<td>24 ± 46</td>
<td>0.902</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P = 0.026</td>
<td>P = 0.011</td>
<td></td>
</tr>
<tr>
<td>Training 4–6 months</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endurance training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>225 ± 50</td>
<td>225 ± 54</td>
<td>0.956</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>268 ± 160</td>
<td>278 ± 157</td>
<td>0.989</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P = 0.093</td>
<td>P = 0.204</td>
<td></td>
</tr>
<tr>
<td>Strength training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target TRIMP per week</td>
<td>22 ± 10</td>
<td>20 ± 10</td>
<td>0.082</td>
</tr>
<tr>
<td>Realized TRIMP per week</td>
<td>17 ± 19</td>
<td>25 ± 55</td>
<td>0.240</td>
</tr>
<tr>
<td>P-level target versus realized</td>
<td>P = 0.002</td>
<td>P = 0.001</td>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SD; n, number of subjects; CAD, coronary artery disease; T2D, type 2 diabetes; TRIMP, training impulse.

patients with CAD+T2D had lower exercise capacity and lower maximal heart rate than the patients with CAD (Table 2), for example, the maximal heart rate was 128 ± 19 versus 139 ± 19 bpm for the CAD+T2D versus patients with CAD, respectively (P = 0.011). Differences in exercise capacity and maximal heart rate between groups did not remain statistically significant after adjustment for BMI. Maximal exercise capacity increased in both patients groups from 8.1 ± 2.0 to 8.4 ± 1.9 METs and from 6.5 ± 1.6 to 6.9 ± 1.7 METs for the patients with CAD and CAD+T2D, respectively (main effect for time P<0.001), but there was no main effect for time × group interaction in patients with CAD or CAD+T2D. Moreover, maximal workload and VO2peak increased specially in patients with CAD+T2D, for example, VO2peak from 1.92 ± 0.5...
CAD interaction in any clinical variables in patients with CAD or without T2D (weight, BMI, systolic and diastolic blood pressure and HbA1c). In clinical variables, main effect for time was observed in patients with CAD and CAD+T2D. Similarly, increased levels of high-intensity PA, measured by a questionnaire, have been observed during a 3-month home-based cardiac rehabilitation programme (Blanchard et al., 2010). Previous studies have shown that high-intensity exercise is more effective in increasing cardiorespiratory fitness (Oberman et al., 1995; O’Donovan et al., 2005), ventilatory threshold (Jensen et al., 1996), and left ventricular ejection fraction (Oberman et al., 1995) than low-intensity exercise in men with CAD. Improvements in maximal oxygen uptake are higher in high-intensity exercise than in low-intensity exercise, regardless of equal energy cost (O’Donovan et al., 2005). Therefore, our findings that patients with CAD increased their high-intensity PA by 50% during exercise prescription can be considered clinically relevant.

In patients with diabetes, high-intensity PA seems to be associated with a lower incidence of acute coronary events, whereas low-intensity PA has no significant association with development of acute coronary events (Makrilakis et al., 2004). It has been shown that higher-intensity exercise training also produces greater improvement in maximal oxygen uptake and HbA1c in patients with diabetes (Boule et al., 2003). In addition, the duration of high-intensity activities is an important component in current PA recommendations for CAD patients with T2D (Piepoli et al., 2010).

**Clinical variables after exercise prescription**

In patients with T2D, exercise training improves cardiorespiratory fitness (Boule et al., 2003) and has a positive influence on blood glucose control (Boule et al., 2001; Snowling & Hopkins, 2006; Thomas et al., 2006; Colberg et al., 2010). We found that a controlled 6-month exercise prescription is an effective way to increase cardiorespiratory fitness, defined as VO2peak, among patients with CAD+T2D. Interestingly, we did not find a statistically significant decrease in HbA1c in patients with diabetes during the exercise prescription. This finding may be partly related to the fact that the patients in the present study have good control of their blood glucose level and their HbA1c levels at the baseline were lower on average compared with patients with diabetes in previous studies (6.0 ± 0.7 versus 8.9 ± 1.8%, respectively) (Boule et al., 2001; Snowling & Hopkins, 2006).

Some previous studies have shown that exercise is beneficial for weight reduction in patients with T2D (Agurs-Collins et al., 1997; Balducci et al., 2010). However, no differences in body weight changes were observed between the exercise and control group in a meta-analysis (Boule et al., 2001). In the present study, we did not find significant reduction in BMI in patients with CAD+T2D suggesting that exercise alone without

---

**Clinical variables**

In clinical variables, main effect for time was observed in weight, BMI, systolic and diastolic blood pressure and HbA1c (P<0.05), but there was no main effect for time × group interaction in any clinical variables in patients with CAD or CAD+T2D (Table 1).

**Discussion**

The main finding of this study is that patients with CAD+T2D are physically less active than CAD patients without T2D, documented by objective measurement of daily PA. This difference is largely a result of obesity, i.e. higher BMI of patients with diabetes compared to their non-diabetic counterparts. Moreover, patients with CAD+T2D had lower cardiorespiratory fitness and maximal exercise capacity than age-matched patients with CAD. However, carefully tailored exercise prescriptions based on maximal exercise tests and individual heart rate zones resulted in increased high-intensity PA and exercise capacity in both patient groups.

**Physical activity after exercise prescription**

Our data showed that controlled 6-month exercise prescriptions increased particularly high-intensity PA among CAD patients with and without T2D. Similarly, increased levels of high-intensity PA, measured by a questionnaire, have been observed during a 3-month home-based cardiac rehabilitation programme (Blanchard et al., 2010). Previous studies have shown that high-intensity exercise is more effective in increasing cardiorespiratory fitness (Oberman et al., 1995; O’Donovan et al., 2005), ventilatory threshold (Jensen et al., 1996), and left ventricular ejection fraction (Oberman et al., 1995) than low-intensity exercise in men with CAD. Improvements in maximal oxygen uptake are higher in high-intensity exercise than in low-intensity exercise, regardless of equal energy cost (O’Donovan et al., 2005). Therefore, our findings that patients with CAD increased their high-intensity PA by 50% during exercise prescription can be considered clinically relevant.

In patients with diabetes, high-intensity PA seems to be associated with a lower incidence of acute coronary events, whereas low-intensity PA has no significant association with development of acute coronary events (Makrilakis et al., 2004). It has been shown that higher-intensity exercise training also produces greater improvement in maximal oxygen uptake and HbA1c in patients with diabetes (Boule et al., 2003). In addition, the duration of high-intensity activities is an important component in current PA recommendations for CAD patients with T2D (Piepoli et al., 2010).

**Physical activity before exercise prescription**

In the present study PA was investigated objectively with an accelerometer in CAD patients with and without T2D carefully matched by age, sex and ejection fraction. We found that patients with CAD+T2D are more passive than CAD patients without diabetes. Secondly, at the intensity of brisk walking or higher, the average time of PA was very low among both study groups. The recommendations for brisk walking or higher intensity is ≥30 min day−1 on ≥5 days week−1 (Piepoli et al., 2010), whereas we measured an average PA time/day of approximately 5 and 2 min at the intensity of brisk walking or higher for patients with CAD and CAD+T2D, respectively. The measured PA values are far from the recommendations for both groups.

In agreement with the present observations, previous studies based on questionnaires have shown that a majority of patients with CAD do not engage in recommended levels of PA (Nelson et al., 2002; Lin et al., 2004; Resnick et al., 2006; Wofford et al., 2007; Zhao et al., 2008, 2011) and are physically more passive than the healthy population (Morrato et al., 2007; Zhao et al., 2008, 2011). Also, the prevalence of achieving the recommended PA level is significantly lower among CAD+T2D patients compared with their counterparts without T2D (Zhao et al., 2008). In the present study, the average total PA time per day was almost 50 min less in CAD+T2D patients than in CAD patients without T2D. Taken together, our results suggest that it is necessary to develop more intensive PA counselling for patients with CAD populations with or without diabetes.
dietary counselling may not be enough for weight reduction of obese T2D patients with CAD. In line with this observation, the baseline PA differences between patients with CAD and CAD+T2D did not remain significant after adjustment for BMI. This may indicate that differences in PA are more related to overweight than T2D.

**Methodological considerations**

Self-report questionnaires on PA are an easy and inexpensive way to collect information on PA among a large study population. However, it is well known that the reliability and validity of self-administered questionnaires is weak, particularly for the elderly (Forsen et al., 2010), and questionnaires commonly tend to overestimate PA levels (Troiano et al., 2008; Boon et al., 2010). Accelerometers are more reliable tools than questionnaires for measuring PA levels objectively (Troiano, 2005). The most commonly used accelerometers are carried beside the hip or waist during the measurements (Ward et al., 2005; Garatachea et al., 2010), and therefore the main limitation of these accelerometers is the impossibility to detect upper body movements, which are common in the elderly during everyday activities (Garatachea et al., 2010). In the present study, we used new technology where an accelerometer is integrated into a wristwatch, making it very easy to use. Secondly, the device is able to measure separate PA times, even at five different exercise intensities, which gives new perspectives in studying daily PA times among various populations. The device used in the present study was also recently validated against indirect calorimetry (Brugniaux et al., 2010) and showed very high accuracy in detecting PA times at different intensities. Maximal exercise capacity is rather low for cardiac patients, and therefore it was more practical to analyse PA at only two different intensities, expressed as moderate (2–5 METs) and high intensity (>5 METs).

**Limitations**

In the present study PA was measured as time spent at different absolute intensity levels, expressed as moderate (2–5 METs) and high intensity (>5METs). Our PA measurements did not take into account the variations on subjects’ individual fitness levels. An activity requiring a high-intensity PA level (METs >5) may command almost maximal effort among patients with a lower fitness level.

A high number of patients were excluded from the exercise prescription programme in the present study (57% of patients with CAD and 65% of patients with CAD+T2D). All these patients were excluded owing to advanced age or serious co-morbidities. Our exercise prescription was home-based and rather intensive, including almost daily exercise training sessions, and it excluded patients who may not be able to perform the prescription because of contraindication for exercise, for example, severe chest pain or arrhythmias during or postexercise (Frolkis et al., 2003; Dewey et al., 2008).

Moreover, 26% of the patients with CAD and 29% of the patients with CAD+T2D were not willing to participate in the exercise training prescription even though they met the inclusion criteria. There may be various obstacles to participating in the exercise prescription like lack of motivation, depression, or fear of exercise after a cardiac event. The health care system should be able to tackle these obstacles better in future studies, and most importantly, in daily practice.

Finally, 37% of patients with CAD+T2D and 14% of patients with CAD were excluded from the analyses because of incomplete PA measure at the baseline or interruption of exercise intervention before postprescription measurements. It is necessary take into account that most of the excluded patients (77%), especially among patients with CAD+T2D, had problems with the PA measurement. Even though our accelerometer was integrated into a wristwatch, making it very easy to use, many elderly patients were still unwilling or uncertain how to use this technical device. However, only 8% of patients with CAD+T2D and 4% of patients with CAD interrupted exercise training before postprescription measurements mainly because of musculoskeletal problems or lack of motivation. These drop-out rates are remarkably less than those that have been reported in previous studies (Worcester et al., 2004; Yohannes et al., 2007).

**Conclusions**

Our results showed that a controlled 6-month exercise prescription is an effective way to increase objectively measured high-intensity PA among CAD patients with and without T2D. We also found that PA at the intensity of ‘brisk walking or higher’ is very low among all CAD patients with and without diabetes. This indicates that there is a need to develop a more intensive PA counselling strategy for cardiac and diabetic patients.

**Acknowledgments**

The authors would like to thank RN Pirkko Huikuri, RN Paivi Koski, RN Paivi Kastell, and RN Sari Kaarlenkaski for their excellent assistance in this study. This study is partly funded by Finnish Technology Development Centre (TEKES, Helsinki, Finland), Polar Electro Oy (Kempele, Finland) and Hur Oy (Kokkola, Finland).

**Conflict of interest**

The authors declare that they have no conflict of interest.
References


© 2012 The Authors
Clinical Physiology and Functional Imaging © 2012 Scandinavian Society of Clinical Physiology and Nuclear Medicine 32, 6, 445–454


